The CCDC9 Knockout NCI-H1299 Polyclonal Cells are a CRISPR/Cas9-edited polyclonal cell population in which the CCDC9 tumor suppressor gene has been disrupted across a heterogeneous pool of NCI-H1299 non-small cell lung carcinoma cells. This format avoids the pitfalls of monoclonal selection, providing a more representative loss-of-function system that minimizes site-specific integration biases. The cells are optimized for functional studies of CCDC9 and the Wnt/??-catenin pathway in lung cancer.
NCI-H1299 is an extensively characterized epithelial cell line derived from a lymph node metastasis of a lung adenocarcinoma. Widely used as a tumorigenic model for NSCLC, these cells lack functional p53 and exhibit aggressive proliferation and invasion, reflecting advanced disease. Their well-documented signaling networks make them an ideal host for targeted gene disruption to investigate oncogenic mechanisms.
CCDC9 encodes a coiled-coil domain-containing tumor suppressor that inhibits Wnt/??-catenin signaling. It binds ??-catenin and destruction complex partners GSK3?? and Axin, promoting ??-catenin degradation and thereby repressing TCF/LEF target genes such as MYC and CCND1, which are critical for proliferation. CCDC9 also modulates apoptosis via BCL2 and BAX. Frequently silenced by promoter hypermethylation, its activity is opposed by WNT3A ligand acting via Frizzled and Dishevelled. Consequently, CCDC9 is a pivotal negative regulator of the pathway, and its loss unleashes harmful transcriptional programs.
In the NCI-H1299 lung adenocarcinoma background, CRISPR/Cas9-mediated knockout of CCDC9 removes this regulation, resulting in enhanced ??-catenin/TCF activity and upregulation of oncogenic targets. This polyclonal model allows direct comparison with parental cells to dissect CCDC9-dependent phenotypes such as increased proliferation, migration, and invasion. The heterogeneous edit pool reduces bias from individual guide RNA events, providing robust and reproducible functional data.
These knockout cells are suitable for diverse experimental approaches. Western blotting and RT-qPCR can validate CCDC9 disruption and quantify downstream effectors like MYC, CCND1, BCL2, and BAX. Cell proliferation, Transwell migration, and Matrigel invasion assays directly measure tumorigenic behavior. TOP/FOP flash luciferase reporters assess Wnt pathway activity, while co-immunoprecipitation enables study of ??-catenin, GSK3??, and Axin interactions. Flow cytometry facilitates apoptosis detection, and the cells support drug sensitivity testing and RNA-seq-based transcriptomics. For further details, contact Ascent Research.
